Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molnupiravir - Ridgeback Biotherapeutics

Drug Profile

Molnupiravir - Ridgeback Biotherapeutics

Alternative Names: EIDD-2801; MK-4482

Latest Information Update: 31 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University
  • Developer Emory University; Ridgeback Biotherapeutics
  • Class Antivirals; Esters; Ribonucleosides; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis

Most Recent Events

  • 08 Oct 2020 Merck Sharp & Dohme plans a phase II/III trial ((MK-4482-001) for COVID-2019 infections (In Adults) in October 2020 (PO) (NCT04575584)
  • 05 Oct 2020 Merck Sharp & Dohme plans a phase II/III trial for COVID-2019 infections in October 2020 (NCT04575597)
  • 11 Aug 2020 Ridgeback Biotherapeutics completes the first-in-human phase I trial in COVID-2019 infections in United Kingdom (PO) (NCT04392219)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top